HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies
NCT01119066
Completed
The purpose of this study is to find out the effects of using a system called CliniMACS to remove Tcells from blood stem cells. Removing T-cells may help stop a side effect called Graft-Versus-Host Disease (GVHD). Some studies have been done with CliniMACS, but the Food and Drug Administration (FDA) has not yet approved it.
Gender:
ALL
Ages:
69 years and below
Trial Updated:
07/11/2022
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Multiple Myeloma
Register for Updates
CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies
NCT02529813
Completed
This phase I clinical trial studies the side effects and best dose of CD19-specific T-cells in treating patients with lymphoid malignancies that have spread to other places in the body and usually cannot be cured or controlled with treatment. Sometimes researchers change the deoxyribonucleic acid (DNA) (genetic material in cells) of donated T-cells (white blood cells that support the immune system) using a process called "gene transfer." Gene transfer involves drawing blood from the patient, and... Read More
Gender:
ALL
Ages:
Between 1 year and 80 years
Trial Updated:
06/29/2022
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Blasts 5 Percent or More of Bone Marrow Nucleated Cells, CD19 Positive, Minimal Residual Disease, Non-Hodgkin Lymphoma, Small Lymphocytic Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia
Register for Updates
Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant
NCT01640301
Terminated
This phase I/II trial studies the side effects of laboratory-treated T cells and to see how well they work in treating patients with high-risk acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or chronic myelogenous leukemia (CML) that has returned after a period of improvement (relapsed), previously treated with donor stem cell transplant. Biological therapies, such as cellular adoptive immunotherapy, may stimulate the immune system in different ways and stop cancer cells from growi... Read More
Gender:
ALL
Ages:
All
Trial Updated:
06/28/2022
Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington
Conditions: Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia, Donor, Hematopoietic Cell Transplant Recipient, HLA-A*0201 Positive Cells Present, Recurrent Acute Myeloid Leukemia
Register for Updates
Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
NCT03023046
Completed
This phase II trial studies how well etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin (DA-EPOCH) works in treating patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Drugs used in chemotherapy, such as etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2022
Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington
Conditions: Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
Register for Updates
NMA Haplo or MUD BMT for Newly Diagnosed Severe Aplastic Anemia
NCT02833805
Completed
Our primary objective is to determine if it is feasible for previously untreated severe aplastic anemia (SAA) patients to be transplanted using non-myeloablative conditioning and post transplantation cyclophosphamide.
Gender:
ALL
Ages:
All
Trial Updated:
06/16/2022
Locations: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
Conditions: Severe Aplastic Anemia, Aplastic Anemia, Bone Marrow Failure, Immunosuppression
Register for Updates
A Phase 2 Trial for Men With Metastatic Prostatic Adenocarcinoma
NCT04090775
Completed
This study seeks to estimate the occurrence of adverse events related to the study treatment (Cryosurgical freezing and Intratumoral Combination Immunotherapy), as well as determine the potential efficacy.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/15/2022
Locations: Antelope Valley Urology & Incontinence, Lancaster, California +1 locations
Conditions: Metastatic Prostatic Adenocarcinoma
Register for Updates
A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer
NCT01966471
Completed
This two-arm, randomized, open-label, multicenter study will evaluate the efficacy and safety of trastuzumab emtansine in combination with pertuzumab versus trastuzumab in combination with pertuzumab and a taxane as adjuvant therapy in participants with human epidermal growth (HER) factor 2 (HER2)-positive primary invasive breast cancer. Following surgery and anthracycline-based chemotherapy, participants will receive either trastuzumab emtansine at a dose of 3.6 milligrams per kilogram (mg/kg)... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2022
Locations: HonorHealth Research Institute - Bisgrove, Scottsdale, Arizona +294 locations
Conditions: Breast Cancer
Register for Updates
NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma
NCT01451515
Completed
This is a phase II clinical trial using risk-adapted therapy. The treatment is acute lymphoblastic leukemia (ALL)-based therapy, using multi-agent regimens comprising of induction, consolidation, and continuation (maintenance) phases delivered over 24-30 months. Participants will be classified into 3 treatment stratums, based on bone marrow/peripheral blood lymphoma cells involvement at diagnosis and day 8 for T-lymphoblastic lymphoma and bone marrow/peripheral blood lymphoma cells involvement a... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
06/07/2022
Locations: Rady Children's Hospital San Diego, San Diego, California +1 locations
Conditions: Lymphoblastic Lymphoma
Register for Updates
Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma
NCT00712582
Completed
About 60% of patients with DLBCL can be cured with a chemotherapy program. It is called RCHOP-21 (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone). It is given once every 3 weeks, for 18 weeks. Each three weeks is a cycle. Some factors predict that you may not be cured with R-CHOP-21. The most common ones are: * Stage - how much DLBCL, PMBL, or FL3B you have * LDH - a blood chemistry marker; and * Whether you can do your normal daily activities. (performance status) We thi... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/23/2022
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Non-Hodgkin's Lymphoma
Register for Updates
Umbilical Cord Blood Transplant for Children With Myeloid Hematological Malignancies
NCT01247701
Completed
In this study, the investigators will use busulfan and cyclophosphamide (BuCy) backbone with the addition of fludarabine as the preparative Stem Cell Transplant (SCT) regimen. As an attempt to improve engraftment rate and reduce infections, the investigators are going to incorporate fludarabine in the conditioning regimen. The use of a BuCy backbone has been widely used and comparable to total body irradiation and cyclophosphamide (Cy/TBI) regimen. Encouraging data on adding fludarabine to the... Read More
Gender:
ALL
Ages:
17 years and below
Trial Updated:
05/13/2022
Locations: Texas Children's Hospital, Houston, Texas
Conditions: Myeloid Hematological Malignancies
Register for Updates
Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis
NCT03303950
Terminated
This phase II trial studies how well busulfan, fludarabine, donor stem cell transplant, and cyclophosphamide in treating participants with multiple myeloma or myelofibrosis. Drugs used in chemotherapy, such as busulfan, fludarabine, and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before a donor stem cell transplant helps stop the growth of cells in... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/03/2022
Locations: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
Conditions: Anemia, ASXL1 Gene Mutation, EZH2 Gene Mutation, IDH1 Gene Mutation, IDH2 Gene Mutation, Plasma Cell Myeloma, Primary Myelofibrosis, Recurrent Plasma Cell Myeloma, Secondary Myelofibrosis, Thrombocytopenia
Register for Updates
Combination Chemotherapy With or Without Sodium Thiosulfate in Preventing Low Platelet Count While Treating Patients With Malignant Brain Tumors
NCT00075387
Unknown
This randomized phase II trial studies how well giving combination chemotherapy with or without sodium thiosulfate works in preventing low platelet count while treating patients with malignant brain tumors. Drugs used in chemotherapy, such as carboplatin, cyclophosphamide, and etoposide phosphate, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Sodium thiosulfate may prevent low platelet co... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/29/2022
Locations: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota +2 locations
Conditions: Malignant Glioma
Register for Updates